News Archive

April 2019

• In The NewsApr 11, 2019

  How to be a boss in an unbossed company

  In this interview, Novartis CEO Vas Narasimhan sits down with CNNMoney Switzerland’s Urs Gredig and shares why he thinks innovation should come from the bottom and how wearing jeans and no…
• Media ReleaseApr 11, 2019

  Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries

  Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine…
• 
  StoryApr 09, 2019

  Counting on combos for complex liver diseases

  The best treatment for multifaceted diseases like NASH may be combinations of drugs.

• Featured NewsApr 09, 2019

  Alcon becomes a separately traded standalone company

  On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

• Media ReleaseApr 09, 2019

  Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off

  Novartis positioned for sustained growth, including plans to improve Innovative Medicines core margins into mid-30s by 2022 Novartis has a catalyst-rich pipeline with 10 potential blockbuster…
• 
  StoryApr 08, 2019

  Bringing gene therapy into focus

  Dr. Botond Roska says we should keep our eyes on gene therapy.

• Media ReleaseApr 04, 2019

  Novartis updates on the migraine collaboration with Amgen

  Basel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of…
• In The NewsApr 04, 2019

  Medicines and transformative effect

  In this Bloomberg interview, Vas Narasimhan, CEO of Novartis shares his thoughts on how medicines can have a transformative effect.
• Media ReleaseApr 03, 2019

  Sandoz resubmits biosimilar pegfilgrastim application to US FDA

  Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim  Pegfilgrastim is used to reduce the incidence of neutropenia, one…
• Featured NewsApr 02, 2019

  Sustaining the momentum toward universal health coverage in Africa

  The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019.

• Media ReleaseApr 02, 2019

  Novartis first-in-class Cosentyx® approved in China for psoriasis patients

  China Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy  Cosentyx is…
• Media ReleaseApr 01, 2019

  AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado

  Facility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy …